z-logo
open-access-imgOpen Access
Drug Lag for Inflammatory Bowel Disease Treatments in the East and West
Author(s) -
Shinji Okabayashi,
Taku Kobayashi,
Toshifumi Hibi
Publication year - 2018
Publication title -
inflammatory intestinal diseases
Language(s) - English
Resource type - Journals
eISSN - 2296-9403
pISSN - 2296-9365
DOI - 10.1159/000491878
Subject(s) - ulcerative colitis , medicine , inflammatory bowel disease , drug , european union , disease , lag time , pharmacology , biology , biological system , business , economic policy
Inflammatory bowel disease (IBD), though historically common in the West, is now increasingly prevalent in industrializing countries. A simultaneous dramatic increase in IBD drug options has enabled most patients to achieve remission. Nevertheless, worldwide disparities in the approval of IBD drugs, or "drug lag", remain problematic.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here